Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BGMD Today's stop loss just triggered so my <8.26%> is now realized. Not sure if the oscillator is having the occasional bad day or if my entry was just plain poor today. Whatever the reason b I am out again.
I will keep an eye on it for the next session or 2 and see if it was just my poor trading or the oscillator not work this time.
The concept of buying on Red days is 100% correct, assuming they are not constantly strung together. It is easy to lose liquidity when you have several Red days in a row or when the green days are very meager and mixed in.
Then there may not be much to sell.
For now it seems like just a waiting game 4 me at least, nothing 2 flip that I would make much on and plenty that are pink to red.
Oh well time for a good longgggggggggg walk. lol
BOL
T2M
AVNR Last 4 qtrs seems to burn an *average of $18.5M per quarter, having * around 43M that would be currently available. Imho
That may say cash is drained within the next 2 qtrs or maybe there is an ATM in place (didn't look). Hence if not, some sort of ATM, or offering, or milestone may well be needed before the PDUFA in Nov.
The company enterprise value/share is very near where we are.
Should be an interesting ride but inho we will have to keep an eye open for some event to raise cash with before the Nov PDUFA..
Companies should Raise cash when they don't need it, vs when they do need it and get a tad desperate, if it is a share offering the stockholders end up better usually that way.
Personally I would love to see some rallying events in light of the above observation. Time will tell as it always does.
BOL
T2m
Sheff - not sure that I am not following that example now but I love the oscillator, unfortunately without it, I would not have paid attention. lol
GTXI <Link back> my thought is that the analysts now come out of the wood work since the SP has been in the toilet so long and it has now over months created a very solid base range to work from.
Upcoming catalyst in June 30 or b4 for Metastatic Breast cancer approx date so could be anytime in 2nd qtr.
IF this phase meets end points that could well give this a huge boost due to breast cancer test basis.
Bol
T@M
BS - nice gain - now comes the tough part, when to exit? lol Kudos on the trade!
CLNE We are only trading 1.3 times book. The Revs are up 26% but the free Cashflow fell off and the profits are elusive. If anyone has seen a good B/E numbers from the company please put it up.
I would settle for a FREE CASHFLOW DATE - that seems a bit elusive though.
Interesting Figures and trends to keep in mind as we wade our way thru the maze:
http://ih.advfn.com/p.php?pid=financials&symbol=N^CLNE
bobbo - The process as you may, or may not, know is very involved and time consuming even with Orphan status and priority reviews it takes a fair bit. If the phases proceed they should provide a catalyst for data and eventually hopefully an NDA, and ADCOM and or PDFUA.
Some general FDA Phase time frames plusssss much else, for any who are interested.
http://www.patientnetwork.fda.gov/learn-how-drugs-devices-get-approved/drug-development-process/step-3-clinical-research?gclid=CMKztI7vrb0CFTMV7Aod11gAIA#phases
pack - I think the company has very good prospects and imho it has always been, and remains, as much about time horizon as anything.
You guys listed the Nice articles out: Patent, Phase2 and the agreement, all are strong signs for the stock.
Visibility is the name of the game imo.- since it = greater demand and that coupled with a moderately growing share supply will = >SP and more visibility.
Thanks for the heads up CJ
CLNE Down but not out. Good News Article - Imhmo it is a time horizon thing and trying to anticipate this month or next year is very difficult. The stock suffered a 30% decline last year, but as most things in the stock market, it too will have its day. jmho
http://seekingalpha.com/article/2106873-clean-energy-fuels-down-but-not-out?isDirectRoadblock=false&source=email_rt_article_readmore&uprof=51
Right on the money thus far with your Aug prediction. One to definitely watch shorter term for dips on.
Kudos
T2M
ECYT wow and a few months back it was under $11 man some will make a ton of money off this. Being as it is over $30 pm
Senderos that will be a very interesting to know, TIA
KIPS Volume Alert nearly 2x 20MAVOL VN volume and 10% increase today.
Watch for follow through volume today toward the close that is important to a new leg.
BOL
SMURF Yes I own NAVB PDUFA in June -
ICBU Got out with 20% gain. Just wanted the cash. BOL on it
NAVB Yes I got in a while ago and have flipped it a fair bit over the course of a year. I have it in a few different accounts. I put a chart up on it the other day it has 2 PUDFA dates
NAVB 3/19 5:30PM Navidea Biopharma provides update on European Marketing Authorization Application for Lymphoseek: 'Committee will continue with its review of the MAA' (NAVB) 1.99 -0.04 : Co announced that it held an update meeting with the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the pending Marketing Authorization Application (MAA) of Lymphoseek (technetium Tc 99m tilmanocept) Injection. Lymphoseek is a lymphatic mapping agent designed to identify the lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer. As part of the MAA review process, Navidea presented Oral Explanations to the CHMP relating to open questions in the Lymphoseek MAA. At the conclusion of the meeting, the CHMP informed Navidea that the Committee will continue with its review of the MAA. Navidea believes the course of the review continues to be supportive of its market development plans and outlook for material revenue generation in Europe beginning in 2015, as previously disclosed.
Based on feedback received at the meeting, Navidea believes that the CHMP has found the safety and efficacy data submitted in the MAA for breast cancer and melanoma to be acceptable. The CHMP will now focus its review on the remaining areas of product specifications unique to the European application and on data from the Phase 3 study in head and neck cancer. During this process, the MAA remains active but the review clock will continue to be stopped while Navidea works with the CHMP to address these remaining areas.
5:30PM 3/19 Navidea Biopharma provides update on European Marketing Authorization Application for Lymphoseek: 'Committee will continue with its review of the MAA' (NAVB) 1.99 -0.04 : Co announced that it held an update meeting with the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the pending Marketing Authorization Application (MAA) of Lymphoseek (technetium Tc 99m tilmanocept) Injection. Lymphoseek is a lymphatic mapping agent designed to identify the lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer. As part of the MAA review process, Navidea presented Oral Explanations to the CHMP relating to open questions in the Lymphoseek MAA. At the conclusion of the meeting, the CHMP informed Navidea that the Committee will continue with its review of the MAA. Navidea believes the course of the review continues to be supportive of its market development plans and outlook for material revenue generation in Europe beginning in 2015, as previously disclosed.
Based on feedback received at the meeting, Navidea believes that the CHMP has found the safety and efficacy data submitted in the MAA for breast cancer and melanoma to be acceptable. The CHMP will now focus its review on the remaining areas of product specifications unique to the European application and on data from the Phase 3 study in head and neck cancer. During this process, the MAA remains active but the review clock will continue to be stopped while Navidea works with the CHMP to address these remaining areas.
NAVB 3/19 News Update tonight so far so good
5:30PM Navidea Biopharma provides update on European Marketing Authorization Application for Lymphoseek: 'Committee will continue with its review of the MAA' (NAVB) 1.99 -0.04 : Co announced that it held an update meeting with the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the pending Marketing Authorization Application (MAA) of Lymphoseek (technetium Tc 99m tilmanocept) Injection. Lymphoseek is a lymphatic mapping agent designed to identify the lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer. As part of the MAA review process, Navidea presented Oral Explanations to the CHMP relating to open questions in the Lymphoseek MAA. At the conclusion of the meeting, the CHMP informed Navidea that the Committee will continue with its review of the MAA. Navidea believes the course of the review continues to be supportive of its market development plans and outlook for material revenue generation in Europe beginning in 2015, as previously disclosed.
Based on feedback received at the meeting, Navidea believes that the CHMP has found the safety and efficacy data submitted in the MAA for breast cancer and melanoma to be acceptable. The CHMP will now focus its review on the remaining areas of product specifications unique to the European application and on data from the Phase 3 study in head and neck cancer. During this process, the MAA remains active but the review clock will continue to be stopped while Navidea works with the CHMP to address these remaining areas.
NAVB Sheff now that is great news especially AH stock got up to 2.27 then fell back some on profit taking, great news for sure though.
"$NAVB believes that the CHMP has found the safety and efficacy data submitted in the MAA for breast cancer and melanoma to be acceptable."
Wow is that a multix5 billion dollar market area, it could blow into a huge potential if they can follow it up and follow it through. jmho
PBMD This one had 2xs its 20MAVOL today on 6% gain. I ride it from the low 1.12-1.3 area up to the $2 area seems to channel fairly well. Key though is to pick it when it starts moving with conviction, otherwise it is like watching paint dry. It is in the Ovarian Cancer Arena so when it is good it goes very well.
The oscillators are still negative now but keep an eye on it. jmho
Just one for a strong watch for you.
ADHXF Looks like it should find support at the 50MA around .65 judging from the chart anyway. Had a great move thus far.
Do you have a link for it?
TIA
T2M
ETRM I added some at 1.16 but I already had a pile 2.36-2.5 so strictly just averaging down today on some.
Sheff called the company and added at 2.12 today
ADCOM is scheduled for June 17th. That should be a nice deal as it hits the streets for a run up.
LN long as something is in the offing it keeps odds on your side. jmho
ISR is really off the wall 167% gain currently. VVN
Kei agreed volume is a major factor almost all the time for now you guys have 3x the 20MAVOL which is good for a move, key will be follow on volume tomorrow.
Any other near by catalyst or was this it?
If not they need some news to keep the ball rolling for ya. jmho
running if you have that one you must be veryyyyyyyyyyyy happy!
CRMMF LN and Kei you guys were pushing it glad it paid off so well. Kudos on that trade
Yup what is it?
ISR wow great - pharma call up 100% today
http://www.thestreet.com/story/12535657/1/why-isoray-isr-hit-a-one-year-high-today.html?puc=yahoo&cm_ven=YAHOO
SYN The new price target of $6 by Maxim is very nice and a long way off from here. On Schwab they have a nice write up of reasoning, I will try to find it elsewhere. Finviz has an article Short story -
8:58 am Synthetic Biologics target raised to $6 at Maxim Group following meetings with mgmt
Maxim Group raises its SYN tgt to $6 from $3. Firm concludes that there are now multiple events ahead, including top-line data for Trimesta (oral estriol) in relapsing/remitting multiple sclerosis in April. In addition, SYN-004 (a second-generation product) should progress to the clinic (for the start of a phase 1b/2 trial) for the prevention of C-difficile infection. SYN-005 (mAb) for pertussis (whooping cough) is another catalyst that has shown compelling animal data (whooping cough is an unmet medical need), as well as the development of SYN-010 for C-IBS and related GI disorders and SYN-001 for life-threatening Acinetobacter (gram negative bacterium) infections.
http://finance.yahoo.com/news/short-story-briefing-com-125001333.html
SYN The new price target by Maxim is very nice and a long way off from here. On Schwab they have a nice write up of reasoning, I will try to find it elsewhere. Finviz has an article Short story -
8:58 am Synthetic Biologics target raised to $6 at Maxim Group following meetings with mgmt
Maxim Group raises its SYN tgt to $6 from $3. Firm concludes that there are now multiple events ahead, including top-line data for Trimesta (oral estriol) in relapsing/remitting multiple sclerosis in April. In addition, SYN-004 (a second-generation product) should progress to the clinic (for the start of a phase 1b/2 trial) for the prevention of C-difficile infection. SYN-005 (mAb) for pertussis (whooping cough) is another catalyst that has shown compelling animal data (whooping cough is an unmet medical need), as well as the development of SYN-010 for C-IBS and related GI disorders and SYN-001 for life-threatening Acinetobacter (gram negative bacterium) infections.
http://finance.yahoo.com/news/short-story-briefing-com-125001333.html